BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9731900)

  • 21. Concomitant endometrial hyperplasia in patients with endometrial carcinoma.
    Gücer F; Reich O; Tamussino K; Bader AA; Pieber D; Schöll W; Haas J; Petru E
    Gynecol Oncol; 1998 Apr; 69(1):64-8. PubMed ID: 9571000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
    Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
    J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA index by image analysis in advanced endometrial carcinoma.
    Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
    J Surg Oncol; 1996 Oct; 63(2):91-4. PubMed ID: 8888800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for recurrence in patients with FIGO stage I and II, intermediate or high risk endometrial cancer.
    Zusterzeel PL; Bekkers RL; Hendriks JC; Neesham DN; Rome RM; Quinn MA
    Acta Obstet Gynecol Scand; 2008; 87(2):240-6. PubMed ID: 18231895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
    Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
    Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma.
    Sakuragi N; Hareyama H; Todo Y; Yamada H; Yamamoto R; Fujino T; Sagawa T; Fujimoto S
    Acta Obstet Gynecol Scand; 2000 Apr; 79(4):311-6. PubMed ID: 10746848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
    Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences.
    Soslow RA; Bissonnette JP; Wilton A; Ferguson SE; Alektiar KM; Duska LR; Oliva E
    Am J Surg Pathol; 2007 Jul; 31(7):979-87. PubMed ID: 17592263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multivariate analysis of DNA ploidy, steroid hormone receptors, and CA 125 as prognostic factors in ovarian carcinoma: a prospective study.
    Eissa S; Khalifa A; Laban M; Mohamed MK; Elian A
    Nutrition; 1995; 11(5 Suppl):622-6. PubMed ID: 8748237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
    Stefansson IM; Salvesen HB; Immervoll H; Akslen LA
    Histopathology; 2004 May; 44(5):472-9. PubMed ID: 15139995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
    Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
    Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
    Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
    Powell MA; Mutch DG; Rader JS; Herzog TJ; Huang TH; Goodfellow PJ
    Cancer; 2002 Jun; 94(11):2941-52. PubMed ID: 12115383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
    dos Reis R; Frumovitz M; Milam MR; Capp E; Sun CC; Coleman RL; Ramirez PT
    Gynecol Oncol; 2007 Dec; 107(3):458-63. PubMed ID: 17854872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
    Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
    Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical stage I and II endometrial carcinoma: multivariate analysis of prognostic factors.
    Mammoliti S; Bruzzone M; Chiara S; Vidali A; Miglio L; Fontana V; Oliva C; Compora E; Giuntini P; Centonze M
    Anticancer Res; 1992; 12(5):1415-8. PubMed ID: 1444199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
    Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Romanini C
    Gynecol Oncol; 1996 Apr; 61(1):16-21. PubMed ID: 8626110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.